Safety and Tolerability of mRNA COVID-19 Vaccines in Kidney Transplant Recipients

Ślizień, Zuzanna; Muchlado, Marta; Kubanek, Alicja; Biedunkiewicz, Bogdan; Renke, Marcin; Komorowska, Karolina; Dębska‐Ślizień, Alicja; Tylicki, Leszek

doi:10.1016/j.transproceed.2022.02.025

Cited by 3 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, not only were the antibody titers generated by vaccination lower than those induced by natural mumps infection [ 42 ], but also the magnitude and duration of cell-mediated immunity were greater after rubella natural infection [ 43 ]. Finally, the safety and tolerability of the COVID-19 vaccination that emerged from this study are in accordance with previous results from adult KTRs [ 28 ]. Ślizień et al reported no serious adverse events after COVID-19 mRNA vaccination in 300 KTRs, while fatigue, headache and myalgia were the most common systemic reactions [ 28 ].…”

Section: Discussionsupporting

confidence: 91%

“…Finally, the safety and tolerability of the COVID-19 vaccination that emerged from this study are in accordance with previous results from adult KTRs [ 28 ]. Ślizień et al reported no serious adverse events after COVID-19 mRNA vaccination in 300 KTRs, while fatigue, headache and myalgia were the most common systemic reactions [ 28 ]. Interestingly, in the same study, systemic reactions were most frequently observed in younger patients [ 28 ].…”

Section: Discussionsupporting

confidence: 91%

“…The positive humoral immune response reported in our meta-analysis is relatively higher compared to that in adult KTRs. Recent literature indicates inadequate seroconversion in adult KTRs with seropositivity following a standard immunization course varying from 30% to 51.4% among different studies [ 25 , 26 , 27 , 28 ]. In addition, in the adult population, older age and longer dialysis vintage before kidney transplantation were indicated as risk factors of a lower seroconversion rate [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…Ślizień et al reported no serious adverse events after COVID-19 mRNA vaccination in 300 KTRs, while fatigue, headache and myalgia were the most common systemic reactions [ 28 ]. Interestingly, in the same study, systemic reactions were most frequently observed in younger patients [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Immunologic Response to SARS-CoV-2 Vaccination in Pediatric Kidney Transplant Recipients: A Systematic Review and Meta-Analysis

Emmanouilidou-Fotoulaki

Karava

Dotis

et al. 2023

Vaccines

View full text Add to dashboard Cite

The pediatric population is at a lower risk of severe SARS-CoV-2 infection compared to adults. Nevertheless, immunosuppression in pediatric and adolescent kidney transplant recipients (KTRs) increases their hazard compared to the general population. This systematic review evaluates the efficacy of SARS-CoV-2 vaccines and determines the risk factors of no seroconversion in this population. PubMed-MEDLINE databases were searched for cohort studies. A meta-analysis was performed using fixed and random effect models. In total, seven studies including 254 patients were further analyzed. The random effect model demonstrated a 63% seroconversion rate (95% CI 0.5, 0.76) following a two-dose schedule, which increased to 85% (95% CI 0.76, 0.93) after the third dose administration. Seropositivity was lower in patients under mycophenolate mofetil compared to azathioprine (OR 0.09, 95% CI 0.02, 0.43). Rituximab administration decreased the seroconversion rate (OR 0.12, 95% CI 0.03, 0.43). The glomerular filtration rate (GFR) was 9.25 mL/min/1.73 m2 lower (95% CI 16.37, 2.13) in patients with no seroconversion. The seroconversion rate was lower in vaccinated compared to infected patients (OR 0.13, 95% CI 0.02, 0.72). In conclusion, vaccination against SARS-CoV-2 in pediatric and adolescent KTRs elicits a humoral response, and a third dose is advised. Previous rituximab administration, antimetabolite therapy with mycophenolate mofetil and lower GFR reduce the likelihood for seroconversion.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Immunologic Response to SARS-CoV-2 Vaccination in Pediatric Kidney Transplant Recipients: A Systematic Review and Meta-Analysis

Emmanouilidou-Fotoulaki

Karava

Dotis

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study

Simone,

Pronzo,

Pesce

et al. 2024

J Nephrol

View full text Add to dashboard Cite

Background Immunocompromised patients show an impaired vaccine response and remain at high risk of severe COVID-19, despite vaccination. Neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed for prophylaxis and treatment. The combination tixagevimab/cilgavimab (AZD7442) has been authorized for emergency use as pre-exposure prophylaxis for COVID-19, but data on safety and efficacy in kidney transplant recipients during the Omicron period are limited. Methods We conducted a multicenter retrospective cohort study including 253 kidney transplant recipients, of whom 98 were treated with tixagevimab/cilgavimab 150 mg/150 mg and 155 who received only four doses of the BNT162b2 mRNA vaccine. Results Only 13.3% of patients developed SARS-CoV-2 infection after the administration of tixagevimab/cilgavimab; in comparison, 34.2% of patients had been infected after the fourth dose of vaccine (p = 0.00013). Most infected patients in the AZD7442 group remained asymptomatic (92.3% vs 54.7%), 7.7% had mild symptoms and none had severe disease, need for hospitalization or died, while in the control group, 9.4% of patients had moderate or severe disease (p = 0.04). Using Kaplan–Meier curves we demonstrated that the controls presented early infection compared to the AZD7442 group (p = 0.000014). No changes in eGFR or proteinuria, assessed before and after the administration, were observed. Conclusions In conclusion, our study showed that tixagevimab/cilgavimab 150/150 mg is effective and safe in preventing infection and severe disease when administered to patients with weak or no response to COVID-19 vaccine. Graphical abstract

show abstract

COVID-19 Vaccine in Renal Transplant Recipients: A Bibliometric-Based Analysis of Trends

Zhou

Wang

et al. 2023

Transplantation Proceedings

View full text Add to dashboard Cite

Safety and Tolerability of mRNA COVID-19 Vaccines in Kidney Transplant Recipients

Cited by 3 publications

References 24 publications

Immunologic Response to SARS-CoV-2 Vaccination in Pediatric Kidney Transplant Recipients: A Systematic Review and Meta-Analysis

Immunologic Response to SARS-CoV-2 Vaccination in Pediatric Kidney Transplant Recipients: A Systematic Review and Meta-Analysis

Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study

COVID-19 Vaccine in Renal Transplant Recipients: A Bibliometric-Based Analysis of Trends

Contact Info

Product

Resources

About